Abstract 321P
Background
Ovarian cancer(OC) is the third most common gynaecological cancer in Indian according to Globocan 2020. The majority of patients are diagnosed in advanced stage III and IV. The aim of this study was to evaluate clinical epidemiology and survival outcomes in patients with epithelial ovarian cancer.
Methods
This was a retrospective analysis of patients with epithelial OC who were treated at Asian Institute of Medical Sciences from 1st January 2016 to 31st December 2020. Patient’s sociodemographic characteristics, clinicopathological details like the stage of cancer, treatment received and follow up details was extracted from medical records. All statistical analysis was performed using Microsoft Excel 2016 and R software (Rx 64 version 3.6.2). Survival was estimated by the Kaplan Meier method and compared by the log-rank test.
Results
251 OC patients records were evaluated, epithelial OC constituted 94%(n=235), with a median age 49 years. Majority 81%(n=190) of the patients were in stage III or IV at the time of diagnosis. The main presenting symptoms were abdominal distension 65%(n=153) and gastrointestinal disturbances including pain abdomen 45%(n=106). The most common histologic types were serous 76%(n=179) followed by mucinous carcinoma 18%(n=42). BRCA testing (germline and somatic) was performed in 80 patients. BRCA1/BRCA2 pathogenic or likely pathogenic variant was found in 25% (n=20) patients. Upfront cytoreductive surgery was done only in 28% (n=65). Interval cytoreductive surgery was done in 66%(n=155) patients. Median overall survival for the entire study cohort was 45 months (95% CI, 32 to 47.5). Median overall survival for stage I, II, III, and IV was 62, 53, 38 and 23 months, respectively.
Conclusions
Most of the patients presented in advanced stage of the disease and have poor outcome. Lack of awareness delayed presentation and late diagnosis are resulting in poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract